The field of life sciences commercialization focuses on bridging the gap between scientific research and global market access. It encompasses activities such as intellectual property licensing, regulatory strategy, clinical validation, manufacturing scalability, and international supply chain management.

In an industry where groundbreaking science often falters at commercial and regulatory hurdles, Genegobio Inc. provides the critical link between ambitious biotech ventures and global market success. As a specialized life sciences investment firm, Genegobio goes beyond financing—it offers expertise in IP commercialization, regulatory strategy, and supply chain intelligence, positioning companies to launch transformative therapies and medical devices across borders.

Jane Zhang, CEO of Genegobio Inc., spoke exclusively to Business Fortune about the company’s science-first philosophy and its success in helping healthcare innovators scale globally. Drawing on years of experience in life sciences and cross-border commercialization, she emphasized how Genegobio’s hands-on partnerships, regulatory expertise, and strategic licensing models have earned the trust of biotech and med-tech clients around the world. Below is an excerpt from the interview.

Interview Highlights

What inspired the founding vision of Genegobio, and how has that vision evolved in response to advancements in biotechnology and healthcare innovation?

The founding vision of Genegobio Inc. was rooted in a commitment to harness cutting-edge biotechnology to address unmet medical and aesthetic needs, improving lives through science-driven solutions. Our goal was to bridge the gap between groundbreaking research and real-world applications, particularly in healthcare and beauty. Over the years, advancements in biotechnology—such as CRISPR gene editing, AI-driven drug discovery, and precision medicine—have reshaped our approach. We’ve evolved from a focus on traditional BioPharma to a broader mission that integrates pharmaceutical-grade innovation with consumer-centric solutions like our BEAUTY XPRO line. This evolution reflects our adaptability to emerging technologies and market demands, ensuring we deliver transformative therapies and products globally while maintaining scientific rigor.

Out-licensing innovative drugs globally involves multiple layers of coordination. What core philosophy guides Genegobio’s strategic preparation before approaching international markets?

At Genegobio, our core philosophy for out-licensing is strategic alignment with global partners who share our commitment to innovation and patient impact. We prioritize thorough market analysis, regulatory compliance, and cultural adaptability to ensure seamless integration into diverse healthcare systems. Our preparation involves building robust data packages that demonstrate clinical efficacy and safety, tailored to meet the regulatory standards of each target market. We also emphasize collaborative partnerships, fostering trust through transparent communication and shared goals. This philosophy enables us to navigate complex international landscapes, from regulatory approvals to market access, ensuring our innovative drugs reach patients efficiently and effectively.

Genegobio specializes in medical and biotech investments. What core criteria do you look for when selecting startups or companies to fund in the life sciences space?

When evaluating startups or companies for investment, Genegobio focuses on three core criteria: scientific innovation, market potential, and operational excellence. First, we seek groundbreaking technologies or therapies with strong intellectual property and clear differentiation, such as novel gene therapies or AI-driven diagnostics, and we actively invite biotechs with innovative products to partner with us to bring their solutions to market. Second, we assess market viability, prioritizing solutions that address significant unmet needs in healthcare or aesthetics with scalable commercial potential, offering our expertise in regulatory navigation and global commercialization to support these ventures. Finally, we look for teams with proven expertise, a clear vision, and robust operational strategies to execute their plans, fostering collaborative partnerships to ensure mutual success.

How does Genegobio address the high costs and long timelines typically associated with new drug development?

Genegobio tackles the high costs and extended timelines of drug development through a multifaceted approach. We leverage advanced technologies like AI and machine learning to streamline drug discovery, optimizing target identification and reducing preclinical testing costs. Strategic partnerships with academic institutions and global BioPharma companies allow us to share resources and expertise, accelerating development while mitigating financial risks. Additionally, we prioritize efficient clinical trial designs, such as adaptive trials, to expedite regulatory approvals. By integrating these strategies, we reduce costs by up to 30% and shorten development timelines without compromising quality, ensuring faster delivery of life-changing therapies to patients.

Could you elaborate on how Genegobio performs due diligence and risk assessment, particularly through on-site audits and evaluating the financial health of suppliers?

Genegobio’s due diligence and risk assessment process is comprehensive, combining on-site audits with financial and operational evaluations to ensure supplier reliability. During on-site audits, our expert teams assess manufacturing facilities for compliance with Good Manufacturing Practices (GMP), quality control measures, and scalability. We evaluate suppliers’ financial health by analyzing key metrics such as revenue stability, debt-to-equity ratios, and cash flow projections, ensuring they can sustain long-term partnerships.

In what ways does BEAUTY XPRO’s approach to anti-aging differ from traditional cosmetic treatments, and how does pharmaceutical science enhance these differences?

BEAUTY XPRO redefines anti-aging by integrating pharmaceutical-grade science into aesthetic solutions, moving beyond the superficial focus of traditional cosmetic treatments. Unlike conventional products that target surface-level concerns, BEAUTY XPRO leverages advanced biotechnologies, such as peptide-based formulations and targeted delivery systems inspired by Nano-Biotechnology, to address cellular aging processes. Our products are developed with rigorous clinical testing, ensuring efficacy and safety comparable to pharmaceutical standards. This scientific foundation allows BEAUTY XPRO to deliver measurable results, such as improved skin elasticity and reduced oxidative stress, setting it apart as a pioneer in science-driven beauty solutions.

How does the brand balance the art of beauty with the science of pharmaceuticals in its product development and marketing strategy?

BEAUTY XPRO strikes a balance between the art of beauty and pharmaceutical science by combining aesthetic appeal with scientific credibility. In product development, we employ pharmaceutical-grade research to create formulations that deliver clinically proven results, while ensuring textures, scents, and packaging resonate with consumers’ desire for luxury and elegance. Our marketing strategy emphasizes this fusion, highlighting the science behind our products—such as proprietary peptide complexes—while showcasing their transformative effects through compelling visuals and client testimonials.

What are your strategic priorities for the next 3–5 years, and how does Genegobio plan to maintain its leadership in healthcare investment and global commercialization?

Over the next 3–5 years, Genegobio’s strategic priorities include expanding our global footprint, advancing our therapeutic pipeline, and scaling BEAUTY XPRO’s market presence, while actively seeking partnerships with biotechs that have innovative products ready for market entry. We aim to enter new markets in BRICS, leveraging strategic collaborations to streamline regulatory approvals and distribution, and we invite biotech innovators to partner with us to navigate these complex landscapes together. To maintain leadership, we will invest in cutting-edge technologies, strengthen our global network of collaborators, and uphold our commitment to innovation and quality, ensuring Genegobio remains a trusted partner for transformative healthcare and aesthetic solutions worldwide.

How do you balance the rigorous demands of pharmaceutical-grade research with the fast-paced innovation needed in the beauty industry, and what compromises, if any, have you had to make to maintain both scientific integrity and market relevance?

Balancing pharmaceutical-grade research with the beauty industry’s fast-paced demands requires a disciplined yet agile approach. Genegobio invests heavily in R&D to ensure our BEAUTY XPRO products meet stringent scientific standards, conducting multi-phase clinical trials to validate efficacy, while inviting biotech with innovative anti-aging solutions to partner with us to accelerate their market entry. To keep pace with market trends, we employ modular development processes, allowing us to iterate formulations quickly without sacrificing quality, and we offer our expertise in regulatory and commercialization strategies to support partners in achieving market relevance.

Jane Zhang | CEO

Jane Zhang is the visionary CEO of Genegobio Inc., a global leader in biotechnology and healthcare investment. With over 15 years of experience in the life sciences, Jane has driven innovation in biopharmaceuticals and aesthetics, spearheading the development of Genegobio’s groundbreaking BEAUTY XPRO line. Holding a Master in Chemistry from State University of New York at Stony Brook, she combines scientific expertise with strategic acumen. Under her leadership, Genegobio has secured over $200 million in investments and forged partnerships across 9 countries, earning recognition as one of Business Forturne’s “Best 30 Companies of 2025.” Jane is passionate about advancing human health and beauty through science-driven solutions.

“No compromises are made on scientific integrity—our commitment to safety and efficacy is non-negotiable—and by leveraging AI-driven research and strategic partnerships, we deliver innovative, market-relevant products while upholding pharmaceutical-grade standards.”